A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06) (VLA-X06)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00832559 |
Recruitment Status :
Terminated
(Poor recruitment rate.)
First Posted : January 30, 2009
Last Update Posted : January 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is designed to assess the safety and initial indications of efficacy resulting from multiple doses of CAVATAK injected directly into solid tumours of the Head and Neck that have been confirmed to express ICAM-1 and DAF.
CAVATAK (Coxsackievirus A21) is a naturally occurring common cold virus that preclinical research indicates can preferentially infect and kill cancer cells expressing the receptors ICAM-1 and/or DAF. This virus is known to cause self limiting upper respiratory infections and has been used previously to challenge therapies against the common cold. The virus is not generically modified.
The study proposes to administer CAVATAK to three cohorts each of three patients. The first cohort will receive a single dose, the second cohort will receive three doses, and the final cohort will receive six doses. There will a 48 hour interval between repeated doses.
The primary objective of the study is to determine the safety and efficacy of CVA21 given by intratumoural injection in the treatment of recurrent, unresectable squamous cell carcinoma of the head and neck by measuring primary and field tumour status and adverse effects.
Secondary objectives of the study are:
- Indirect measurements of efficacy by measuring appropriate biomarkers in serum and tumour biopsy samples for viral replication, induction of apoptosis and anti-tumour immune responses.
- To determine the time course of potential primary and secondary viraemia.
- To characterise the time course of the anti-CVA21 antibody response after administration of CVA21
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer | Biological: CVA21 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 4 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Open-label, Dosage Escalation, Study of Multiple Doses of CAVATAKTM (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors (VLA-X06) |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: CVA21
CVA21
|
Biological: CVA21
1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
Other Names:
|
- Safety and tolerability of patients to multiple doses of CAVATAK [ Time Frame: 1 year ]safety and tolerability

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who are willing and able to provide written informed consent to participate in the study.
- Patients with histologically confirmed metastatic or recurrent squamous cell carcinoma of the head or neck currently documented as "progressive disease"
- Head and neck cancer patients with at least one tumour mass where the tumour mass is accessible for intratumoural injection and can be measured at periodic intervals for tumour size using callipers and/or ultrasound.
- All patients to have histologically confirmed squamous cell carcinoma of the head and neck (excluding nasopharyngeal) that had recurred or relapsed after surgery and/or radiotherapy and/or chemotherapy.
- The longest diameter of the target injectable tumour being no greater than 6 cm or no less than 1 cm in the longest diameter.
- The tumour mass to be intratumourally injected to be easily accessible for injection and amenable to measurement by physical examination and / or radiographically.
- Patients to be 18 years or older
- Absence of circulating antibodies to CVA21 (titre < 1:16).
-
Adequate haematological, hepatic and renal function, defined as:
ANC > 1.5 x 109/L, platelets > 100 x 109/L Bilirubin < 20µmol/L, AST < 2.5 times the upper limit of normal Calculated creatinine clearance > 30 mL/minute
Adequate immunologic function, defined as:
Serum IgG > 5g/L T cell subsets within normal limits
- Fertile males and females must agree to the use of an adequate form of contraception. Hormonal contraceptives should be supplemented with an additional barrier method. Negative pregnancy test is required in female patients of child-bearing potential.
Exclusion Criteria:
- Patients receiving radiotherapy to the proposed injected tumour or radiotherapy within the last 3 weeks
- Performance status > 1 on the ECOG scale
- Life expectancy < 3 months.
- Pregnancy or breastfeeding.
- Primary or secondary immunodeficiency, including immunosuppressive disease, and immunosuppressive doses of corticosteroids (e.g. prednisolone > 7.5mg per day) or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks.
- Positive serology for HIV, Hepatitis B or Hepatitis C.
- Splenectomy.
- Presence of uncontrolled infection.
- Any uncontrolled medical condition that in the opinion of the Investigator is likely to place the patient at unacceptable risk during the study or reduce their ability to complete the study
- Participation in another study requiring administration of an investigational drug or biological agent within the last 4 weeks
- Known allergy to treatment medication or its excipients
- Tumours to be injected lying in mucosal regions or close to an airway, major blood vessel or spinal cord that, in the opinion of the Investigators, could cause occlusion or compression in the case of tumour swelling or erosion into a major vessel in the case of necrosis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00832559
Australia, New South Wales | |
St Vincents Hospital | |
Darlinghurst, New South Wales, Australia, 2010 | |
Calvary Mater Newcastle Hospital | |
Newcastle, New South Wales, Australia, 2310 | |
Australia, Victoria | |
Monash Medical Centre | |
Clayton, Victoria, Australia, 3168 |
Principal Investigator: | Stephen Ackland, MBBS FRACP | Principal Investigator |
Additional Information:
Responsible Party: | Roberta Karpathy, Operations Director, Viralytics |
ClinicalTrials.gov Identifier: | NCT00832559 History of Changes |
Other Study ID Numbers: |
VLA-X06 |
First Posted: | January 30, 2009 Key Record Dates |
Last Update Posted: | January 12, 2018 |
Last Verified: | January 2018 |
Keywords provided by Roberta Karpathy, Viralytics:
CAVATAK Coxsackievirus A21 CVA21 Oncolytic virotherapy |
Additional relevant MeSH terms:
Head and Neck Neoplasms Neoplasms by Site Neoplasms |